Pharma

Innovations a Highlight at Dry Eye Breakout Session

Innovations a Highlight at Dry Eye Breakout Session

By Steve Lenier | January 8, 2020

The dry eye disease (DED) market is expected to have an annual compound growth rate of 4.5% between 2017 and 2025, which should help it…

Read More
BioGenware’s Speculet Seeks to Improve the Patient Experience

BioGenware’s Speculet Seeks to Improve the Patient Experience

By Steve Lenier | December 18, 2019

For those undergoing intravitreal injections (and there are about 22 million of these performed yearly worldwide), a common complaint is that the speculum is uncomfortable,…

Read More
We’ve Got Your BAK

We’ve Got Your BAK

By Michelle Dalton | December 11, 2019

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would…

Read More
CorneaGen Aims to End Corneal Blindness

CorneaGen Aims to End Corneal Blindness

By Vanessa Caceres | December 4, 2019

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has…

Read More
RegenxBio sues FDA over clinical hold

RegenxBio sues FDA over clinical hold

By Keith Croes | November 27, 2019

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined…

Read More
Bausch, Clearside See Gains Post-Deal

Bausch, Clearside See Gains Post-Deal

By Steve Lenier | November 20, 2019

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a…

Read More
OIS INDEX Oyster Point

Oyster Point Pharma Goes Public

By Michelle Dalton | November 14, 2019

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has…

Read More
Digging deep in the retina pipeline

Digging deep in the retina pipeline

By Rich Kirkner | November 13, 2019

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early…

Read More
Ain’t Misbehaving

Ain’t Misbehaving

By Steve Lenier | October 23, 2019

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The…

Read More
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

By Keith Croes | July 17, 2019

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting,…

Read More
Ocular Therapeutix’s Strong Bounce Back

After Re-submitted NDA a Year Ago, Ocular Therapeutix Finds Its Path Forward

By Steve Lenier | June 19, 2019

In July 2018 Ocular Therapeutix re-submitted its New Drug Application for Dextenza to the Food and Drug Administration. At that time, Scott Corning, the company’s…

Read More
Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

By Michelle Dalton | May 14, 2019

VANCOUVER – Novartis is one of the world’s largest ophthalmic pharmaceutical companies, with $4.6 billion in assets as part of the Medicines division, yet some…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.